

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 19 2003

TECH CENTER 1600/2900

Applicants : W. Michael Kavanaugh et al.
Application No. : 09/640,041
Filed : August 15, 2000
For : EGFH2 GENES AND GENE PRODUCTS

Examiner : Michail A. Belyavskyi
Art Unit : 1644
Docket No. : 59516-135 / PP-01615.002
Date : June 12, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO/SB/08 (a copy of the cited reference is enclosed). As to the references supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such references, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are being made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

06/17/2003 HALI11 00000018 040258 09640041


01 FC:1806 180.00 DA

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

A fee of \$180 is submitted in accordance with 37 C.F.R. § 1.97(c). The Commissioner is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 04-0258.

Respectfully submitted,


Davis Wright Tremaine LLP



Jane E. R. Potter
Registration No. 33,332



2600 Century Square
1501 Fourth Avenue
Seattle, WA 98101-1688
Phone: (206) 622-7650
Fax: (206) 628-7699



Express Mail No. EL852691935US

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|-------------------------|-----------------------|------------------------|--------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Compl t if Known | | | |
| | | Applicati n Numb r | 09/640,041 | | |
| | | Filing Date | August 15, 2000 | | |
| | | First Named Inventor | W. Michael Kavanaugh | | |
| | | Art Unit | 1644 | | |
| | | Examiner Name | Michail A. Belyavskiy | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | 59516-135 / PP-01615.002 |

RECEIVED JUN 19 2003 TECH CENTER 1600/2900

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | PINKAS-KRAMARSKI ET AL., <i>Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions</i> , EMBO Jour., 1995, 15:2452-2467 | |
| | | SHELLY ET AL., <i>Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes</i> , J. Biol Chem., 1998, pp. 10496-10505, 273:17 | |
| | | SEPP-LORENZINO, L. ET AL., <i>Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells</i> , Oncogene, 1996, 12:1679-1687 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to